Structure Therapeutics' oral amylin agonist ... The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight loss, raising the benchmark injectables in development.

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Stream NBC 5 for free ...

Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy ...

CagriSema-treated patients achieved superior weight loss compared with those who received placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and ...

The company said a Phase 3 trial showed that after 68 weeks, those who took CagriSema achieved a weight loss of 15.7%, compared with a weight loss of 3.1% for those taking a placebo. Tomi Kilgore ...

At 68 weeks, 89.7% of adults with obesity and type 2 diabetes lost 5% or more body weight with CagriSema. Detailed results from the REDEFINE 1 and REDEFINE 2 trials will be presented later in 2025.